Pimcore vs Roche

UK Investor Tenzing Acquires Majority Stake in Austrian MarTech Pimcore

UK-based technology investor Tenzing has acquired a majority stake in Salzburg-based data management software provider Pimcore. Pimcore, founded in 2009, operates an open-core platform that unifies product, customer, and digital asset data into a single source of truth, serving over 400 enterprise clients globally. The company was previously backed by Munich-based Nordwind Growth, which led a $12 million Series B in 2022 and held approximately a 73% stake. Pimcore's founders, Dietmar Rietsch and Matthias Blauth, will remain on board as co-CEOs to guide international expansion and target potential acquisitions, positioning clean data as a crucial baseline for enterprise AI applications. The acquisition is Tenzing's second deal in the DACH region and is currently pending antitrust regulatory clearance.

• UK tech investor Tenzing is acquiring a majority stake in Salzburg-based Pimcore.
• Previous majority shareholder Nordwind Growth led a $12 million Series B in Pimcore in 2022 and held a 73% stake.
• Pimcore transitioned from an open-source community model to an open-core approach, driving organic growth.

We built the layer enterprise AI is about to crash into. Now we scale it.

Today Nordwind Growth announced an agreement to sell its majority stake in Pimcore to Tenzing, a London-based investor in European B2B software. The transaction remains subject to antitrust approvals.

Wirz Launches Healthcare Consulting Unit Wirz Pulse

Swiss agency group Wirz has launched 'Wirz Pulse', a specialized consulting offering for the healthcare market, targeting hospitals, insurers, and pharma/medtech companies. The service aims to support healthcare organizations in positioning, change management, and growth. Wirz will collaborate with organizations to develop a strategic direction translated into positioning, culture, offerings, communication, and experiences. Six programs cover transformation, brand identity, patient journey, work culture, innovation, and digital experience. The launch responds to labor shortages, cost pressure, digitalization, and evolving patient needs, as well as new fields like personalized medicine and longevity. Existing healthcare mandates include Roche, University Hospital Zurich, CSS, Interpharma, and Rheumaliga Schweiz, from which Wirz derived recurring challenges and success factors.

• Wirz Group launches 'Wirz Pulse' consulting service for healthcare sector.
• Targets hospitals, insurers, pharma, and medtech companies.
• Offers six programs: transformation, brand identity, patient journey, work culture, innovation, digital experience.

Roche and Ypsomed Stay Top in Swiss Reputation Ranking

Swissreputation Group and Pressrelations Schweiz analyzed nearly 90,000 reputation-relevant statements from about 4,000 Swiss online and print sources using an AI-supported method to evaluate media reputation for 40 pharma and medtech companies. The study measured presence (coverage and reach) and tonality (positive/negative reporting) and calculated a Reputation Score (0–100) for each company across six reputation dimensions. In Pharma & Biopharma, Roche ranks first (ahead of MSD, Novartis, Sandoz and AstraZeneca). In MedTech & Diagnostics, Ypsomed remains first (ahead of Medacta, Straumann Group, Alcon and Sonova). The study notes products/services, innovation and economic performance tended to improve media reputation, while workplace issues (layoffs, relocations) and ESG/legal problems harmed reputation. The article was published on 2026-08-13.

• Swissreputation Group and Pressrelations Schweiz analyzed nearly 90,000 reputation-relevant statements from about 4,000 Swiss online and print sources using an AI-supported method.
• The study measured presence and tonality for 40 pharma and medtech companies and computed a Reputation Score between 0 and 100 across six reputation dimensions.
• In the Pharma & Biopharma category, Roche ranked first, followed by MSD, Novartis, Sandoz and AstraZeneca.

Roche Pharma Day 2026 announced

Roche Pharma Day 2026 will be held on Monday, 28th September 2026, 09:00am BST. More details available via the investor update.